Published in Am J Transplant on November 13, 2014
Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. J Am Soc Nephrol (2017) 1.38
Chimerism-based tolerance in organ transplantation: preclinical and clinical studies. Clin Exp Immunol (2017) 0.84
Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance. Curr Opin Organ Transplant (2015) 0.80
Alloreactive Regulatory T Cells Allow the Generation of Mixed Chimerism and Transplant Tolerance. Front Immunol (2015) 0.76
Transplantation: induction of chimerism and immune tolerance using belatacept. Nat Rev Nephrol (2014) 0.75
Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance. Adv Hematol (2016) 0.75
Induced regulatory T cells in allograft tolerance via transient mixed chimerism. JCI Insight (2016) 0.75
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Development and homeostasis of T cell memory in rhesus macaque. J Immunol (2002) 6.88
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 3.77
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A (1997) 3.25
Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18
Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med (1993) 2.62
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med (2000) 2.61
CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant (2004) 2.45
Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med (2000) 2.16
Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med (2011) 1.97
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation (2004) 1.82
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant (2012) 1.79
Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol (1994) 1.77
Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant (2014) 1.70
Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation (1999) 1.66
Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol (1997) 1.55
Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am J Transplant (2012) 1.54
Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation (1997) 1.45
Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeys. Am J Transplant (2010) 1.39
Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant (2010) 1.36
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2013) 1.29
Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant (2013) 1.23
Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation (1999) 1.20
Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant (2011) 1.20
CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant (2011) 1.18
Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. Surgery (1990) 1.11
CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation (1996) 1.01
T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model. J Heart Lung Transplant (2013) 0.96
Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol (2007) 0.95
Monitoring antidonor alloantibodies as a predictive assay for renal allograft tolerance/long-term observations in nonhuman primates. Transplantation (2006) 0.91
CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of Indoleamine-2,3-dioxygenase. Transplantation (2007) 0.90
Prevention of acute lung allograft rejection in rat by CTLA4Ig. Am J Transplant (2002) 0.85
Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker. Immunotherapy (2010) 0.85
Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc (1999) 0.83
Tolerance to vascularized organ allografts in large-animal models. Curr Opin Immunol (1999) 0.81
Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat. Eur Surg Res (2011) 0.79
The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion. Clin Exp Immunol (2004) 0.78
Practice guidelines for the use of subcutaneous abatacept. Reumatol Clin (2014) 0.78
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 16.86
Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A (1987) 14.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J Immunol (1980) 8.56
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J Immunol (1981) 6.75
Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol (1979) 6.70
Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature (1979) 5.58
A mouse B-cell alloantigen determined by gene(s) linked to the major histocompatibility complex. J Exp Med (1973) 5.55
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol (2001) 5.36
Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 4.26
Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol (1993) 4.23
Monoclonal antibodies to mouse major histocompatibility complex antigens. Transplantation (1982) 4.11
Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol (2000) 4.10
Limb and skin abnormalities in mice lacking IKKalpha. Science (1999) 3.85
Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest (1996) 3.73
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Transplantation in miniature swine. I. Fixation of the major histocompatibility complex. Transplantation (1976) 3.41
Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol (1980) 3.39
Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34
Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med (1989) 3.34
Activation of T and B lymphocytes in vitro. III. Presence of Ia determinants on allogeneic effect factor. J Exp Med (1974) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol (2001) 3.26
Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18
International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int (1993) 3.11
Evidence for identity or close association of the Fc receptor of B lymphocytes and alloantigens determined by the Ir region of the H-2 complex. J Exp Med (1974) 3.07
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol (1999) 2.84
Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest (2001) 2.79
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
T lymphocyte-enriched murine peritoneal exudate cells. III. Inhibition of antigen-induced T lymphocyte Proliferation with anti-Ia antisera. J Immunol (1976) 2.64
Preparation and characterization of monoclonal antibodies reactive with porcine PBL. J Immunol (1984) 2.62
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med (2000) 2.61
Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med (2001) 2.57
Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer (1971) 2.56
TLR6: A novel member of an expanding toll-like receptor family. Gene (1999) 2.55
A subpopulation of adherent accessory cells bearing both I-A and I-E or C subregion antigens is required for antigen-specific murine T lymphocyte proliferation. J Immunol (1978) 2.54
B-lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens. J Exp Med (1977) 2.44
Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol (2000) 2.41
Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med (1998) 2.40
Mouse alloantibodies capable of blocking cytotoxic T-cell function. I. Relationship between the antigen reactive with blocking antibodies and the Lyt-2 locus. J Exp Med (1979) 2.39
Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab (1996) 2.37
Production of human alpha-interferon in silkworm using a baculovirus vector. Nature (1985) 2.37
Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A (1988) 2.36
Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J Exp Med (1985) 2.34
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology (1996) 2.28
Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci U S A (1994) 2.26
Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet (1999) 2.26
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 2.22
Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr (1998) 2.21
Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci U S A (1987) 2.17
The immunologic response to xenografts. Recognition of mouse H-2 histocompatibility antigens by the rat. J Immunol (1971) 2.17
Crystallization of a poly(ethylene-co-octene): I. A precursor structure and two competing mechanisms. Eur Phys J E Soft Matter (2005) 2.17
A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant (2011) 2.16
Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 2.16
Pig hematopoietic cell chimerism in baboons conditioned with a nonmyeloablative regimen and CD154 blockade. Transplantation (2002) 2.15
Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc (2005) 2.13
Effective treatment of lymphedema of the extremities. Arch Surg (1998) 2.11
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol (1982) 2.10
Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. Am J Transplant (2014) 2.09
Risk of bile duct carcinogenesis after excision of extrahepatic bile ducts in pancreaticobiliary maljunction. Surgery (1999) 2.09
Resistance to Listeria monocytogenes in mice: genetic control by genes that are not linked to the H-2 complex. J Infect Dis (1979) 2.09
Native portal vein embolization for persistent hyperoxaluria following kidney and auxiliary partial liver transplantation. Am J Transplant (2013) 2.05
Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest (1989) 2.04
The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increases prior to inflammatory cell infiltration. J Immunol (1984) 2.02
Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med (1985) 2.00
A new chromogenic endotoxin-specific assay using recombined limulus coagulation enzymes and its clinical applications. Clin Chim Acta (1985) 1.99
Kidney transplants in mice. An analysis of the immune status of mice bearing long-term, H-2 incompatible transplants. J Exp Med (1978) 1.95
Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab (2001) 1.95
A framework to study the cortical folding patterns. Neuroimage (2004) 1.90
Quantitative Beutler test for newborn mass screening of galactosemia using a fluorometric microplate reader. Clin Chem (2000) 1.90
Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol (1999) 1.89
Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation (2000) 1.88